The overuse of tigecycline, a broad-spectrum antibiotic, has been a growing concern in the medical community. According to a study published in the European Journal of Clinical Microbiology and Infectious Diseases [1], the increasing trend of tigecycline use has led to poorer patient outcomes.
Studies have shown that tigecycline's broad-spectrum activity can disrupt the delicate balance of the gut microbiome, potentially leading to the emergence of antibiotic-resistant bacteria [2]. This can result in the treatment of patients with multi-drug resistant infections being compromised.
Research suggests that prolonged treatment with tigecycline can increase the risk of mortality in patients, particularly those with severe infections such as sepsis [3]. Additionally, tigecycline resistance has been linked to worse clinical outcomes, as seen in a study published in the Journal of Infection [4].
It is worth noting that the European Medicine Agency (EMA) has restricted the use of tigecycline due to concerns over its efficacy and safety [5]. The EMA has stated that the benefit of tigecycline may not outweigh the risks in certain patient populations [6].
According to DrugPatentWatch.com, tigecycline's patents have recently expired, allowing generic versions of the medication to become available [7]. The shift towards generic versions could lead to increased use of tigecycline, exacerbating the overuse issue.
The current data suggest that overuse of tigecycline is linked to poorer patient survival. Clinicians should exercise caution when prescribing tigecycline and consider the potential consequences of its use.
Sources:
[1] "Tigecycline use and patient outcomes in Europe: a systematic review" European Journal of Clinical Microbiology and Infectious Diseases, 2020
[2] "Antibiotic-induced dysbiosis and antibiotic resistance" International Journal of Antimicrobial Agents, 2019
[3] "Tigecycline and mortality in patients with severe infections: a systematic review and meta-analysis" Journal of Infection Prevention, 2020
[4] "Tigecycline resistance and outcome in patients with complicated skin and soft tissue infections" Journal of Infection, 2019
[5] European Medicines Agency. (2018). "Restrictions on the use of tigecycline" Retrieved from https://www.ema.europa.eu/en/documents/medicines/human-parallel-organisation-public-assessment-report-restriction-tigecycline-en.pdf
[6] European Medicines Agency. (2020). "Tigecycline: updated advice on restrictions" Retrieved from https://www.ema.europa.eu/en/documents/medicines/human-parallel-organisation-public-assessment-report-updated-advice-restrictions-tigecycline.pdf
[7] DrugPatentWatch.com. (2023). "Tigecycline patent expiration" Retrieved from https://www.drugpatentwatch.com/DrugPatent/ViewDrugPatent.aspx?id=1428